Responses
Friday 07 October 2022 from 13:00 to 14:10
PO.5 E- poster session 5: lupus nephritis
PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification
Compose a Response to This Article
Other responses
No responses have been published for this article.